{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:50:08Z","timestamp":1791492608742,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["GMUCR2025-02031"],"award-info":[{"award-number":["GMUCR2025-02031"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcms.2026.109906","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:06:58Z","timestamp":1791356818000},"page":"109906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: a two-center real-world retrospective cohort study"],"prefix":"10.1016","volume":"54","author":[{"given":"Huangan","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8552-6763","authenticated-orcid":false,"given":"YunJie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuandong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoNan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcms.2026.109906_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00262-024-03850-y","article-title":"Interdependence of coagulation with immunotherapy and BRAF\/MEK inhibitor therapy: results from a prospective study","volume":"74","author":"Beckmann","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jcms.2026.109906_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating head and neck cancer in the age of immunotherapy: a 2023 update","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jcms.2026.109906_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107348","article-title":"De-escalated surgery following neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: a retrospective cohort study","volume":"165","author":"Cao","year":"2025","journal-title":"Oral Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217095","article-title":"Less is more: exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment","volume":"598","author":"Cao","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jcms.2026.109906_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcms.2026.109906_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcms.2026.109906_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.jcms.2026.109906_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104103","article-title":"Advancing the PD-L1 CPS test in metastatic TNBC: insights from pathologists and findings from a nationwide survey","volume":"190","author":"Fusco","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jcms.2026.109906_bib10","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2015.61.2994","article-title":"Advances in radiotherapy for head and neck cancer","volume":"33","author":"Gr\u00e9goire","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib11","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1097\/JS9.0000000000003023","article-title":"Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial","volume":"111","author":"He","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jcms.2026.109906_bib12","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","article-title":"Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)","volume":"109","author":"Huang","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jcms.2026.109906_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103018","article-title":"Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer","volume":"140","author":"Imamura","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jcms.2026.109906_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcms.2026.109906_bib17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/JS9.0000000000000353","article-title":"Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study","volume":"109","author":"Ju","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jcms.2026.109906_bib18","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(19)30306-7","article-title":"Radioimmunotherapy for the treatment of head and neck cancer","volume":"20","author":"Karam","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcms.2026.109906_bib20","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i8.105099","article-title":"Prognostic value of coagulation markers in locally advanced gastric cancer following neoadjuvant immunochemotherapy","volume":"17","author":"Krishnan","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib21","article-title":"Prediction of early clinical response to neoadjuvant chemotherapy in triple-negative breast cancer: incorporating radiomics through breast MRI","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jcms.2026.109906_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009565","article-title":"FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jcms.2026.109906_bib23","article-title":"Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: randomized, two-arm, phase 2 trial","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jcms.2026.109906_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","article-title":"Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis","volume":"147","author":"Masarwy","year":"2021","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.jcms.2026.109906_bib25","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcms.2026.109906_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jcms.2026.109906_bib28","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.jtha.2023.08.008","article-title":"Coagulation factor VIIa enhances programmed death-ligand 1 expression and its stability in breast cancer cells to promote breast cancer immune evasion","volume":"21","author":"Paul","year":"2023","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.jcms.2026.109906_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis","volume":"22","author":"Petit","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib30","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcms.2026.109906_bib31","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jcms.2026.109906_bib33","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcms.2026.109906_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcms.2026.109906_bib34","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jcms.2026.109906_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115027","article-title":"The role of coagulome in the tumor immune microenvironment","volume":"200","author":"Wahab","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jcms.2026.109906_bib36","article-title":"Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jcms.2026.109906_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcms.2026.109906_bib38","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jcms.2026.109906_bib39","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1038\/s41467-025-59004-w","article-title":"Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial","volume":"16","author":"Xiang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jcms.2026.109906_bib40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3892\/ol.2023.13855","article-title":"Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second-line treatment","volume":"25","author":"Xu","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jcms.2026.109906_bib41","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/0008-5472.CAN-18-3206","article-title":"Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1-dependent immune evasion","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.jcms.2026.109906_bib42","first-page":"213","article-title":"Neoadjuvant chemotherapy for advanced oral cavity cancer","volume":"74","author":"Yaniv","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jcms.2026.109906_bib43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcms.2026.109906_bib44","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcms.2026.109906_bib45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","article-title":"T cell dynamics with neoadjuvant immunotherapy in head and neck cancer","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518226054636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518226054636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:12:15Z","timestamp":1791490335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518226054636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1010518226054636"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2026.109906","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of neoadjuvant chemoimmunotherapy for locally advanced oral squamous cell carcinoma: a two-center real-world retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2026.109906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109906"}}